Royal Bank Of Canada set a $18.00 price target on Valeant Pharmaceuticals International, Inc. (NYSE:VRX) (TSE:VRX) in a report released on Wednesday. The brokerage currently has a sector perform rating on the specialty pharmaceutical company’s stock.

Other research analysts also recently issued reports about the stock. Canaccord Genuity set a $14.00 price objective on shares of Valeant Pharmaceuticals International and gave the stock a hold rating in a report on Thursday, August 10th. Rodman & Renshaw reissued a neutral rating and issued a $17.00 price target on shares of Valeant Pharmaceuticals International in a report on Thursday, August 10th. Zacks Investment Research downgraded shares of Valeant Pharmaceuticals International from a hold rating to a strong sell rating in a report on Thursday, July 13th. Piper Jaffray Companies reissued a sell rating and issued a $14.00 price target on shares of Valeant Pharmaceuticals International in a report on Sunday, September 17th. Finally, BMO Capital Markets reissued a hold rating and issued a $15.00 price target on shares of Valeant Pharmaceuticals International in a report on Thursday, July 27th. Five analysts have rated the stock with a sell rating, eleven have issued a hold rating, six have issued a buy rating and one has issued a strong buy rating to the company. The stock presently has an average rating of Hold and a consensus target price of $17.17.

Valeant Pharmaceuticals International (NYSE:VRX) traded up $0.03 on Wednesday, reaching $15.38. 19,959,000 shares of the company traded hands, compared to its average volume of 17,993,862. The company has a market cap of $5,361.35, a P/E ratio of 2.50, a PEG ratio of 0.43 and a beta of -0.40. Valeant Pharmaceuticals International has a 52 week low of $8.31 and a 52 week high of $18.71. The company has a debt-to-equity ratio of 4.84, a quick ratio of 1.10 and a current ratio of 1.26.

COPYRIGHT VIOLATION NOTICE: This news story was posted by Daily Political and is the property of of Daily Political. If you are viewing this news story on another domain, it was copied illegally and republished in violation of U.S. and international copyright and trademark laws. The correct version of this news story can be read at https://www.dailypolitical.com/2017/11/12/valeant-pharmaceuticals-international-inc-vrx-given-a-18-00-price-target-by-royal-bank-of-canada-analysts.html.

In other news, Director Schutter Richard U. De acquired 10,000 shares of the firm’s stock in a transaction on Monday, August 21st. The shares were purchased at an average price of $14.33 per share, for a total transaction of $143,300.00. Following the completion of the transaction, the director now owns 77,479 shares of the company’s stock, valued at $1,110,274.07. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. 5.87% of the stock is currently owned by insiders.

Several hedge funds have recently added to or reduced their stakes in the business. Paulson & CO. Inc. increased its position in shares of Valeant Pharmaceuticals International by 12.5% in the second quarter. Paulson & CO. Inc. now owns 21,813,400 shares of the specialty pharmaceutical company’s stock valued at $377,372,000 after acquiring an additional 2,428,900 shares during the period. Vanguard Group Inc. increased its position in shares of Valeant Pharmaceuticals International by 4.2% in the second quarter. Vanguard Group Inc. now owns 7,274,717 shares of the specialty pharmaceutical company’s stock valued at $125,853,000 after acquiring an additional 294,643 shares during the period. Bank of Montreal Can increased its position in shares of Valeant Pharmaceuticals International by 9.8% in the second quarter. Bank of Montreal Can now owns 6,330,670 shares of the specialty pharmaceutical company’s stock valued at $109,521,000 after acquiring an additional 564,215 shares during the period. CIBC World Markets Inc. increased its position in shares of Valeant Pharmaceuticals International by 2.3% in the second quarter. CIBC World Markets Inc. now owns 3,741,413 shares of the specialty pharmaceutical company’s stock valued at $64,726,000 after acquiring an additional 83,592 shares during the period. Finally, Chou Associates Management Inc. increased its position in shares of Valeant Pharmaceuticals International by 29.7% in the second quarter. Chou Associates Management Inc. now owns 3,053,843 shares of the specialty pharmaceutical company’s stock valued at $53,030,000 after acquiring an additional 700,000 shares during the period. Hedge funds and other institutional investors own 49.74% of the company’s stock.

About Valeant Pharmaceuticals International

Valeant Pharmaceuticals International, Inc is a pharmaceutical and medical device company. The Company is engaged in developing and marketing a range of branded, generic and branded generic pharmaceuticals, over-the-counter (OTC) products, and medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment, and aesthetics devices).

Analyst Recommendations for Valeant Pharmaceuticals International (NYSE:VRX)

Receive News & Ratings for Valeant Pharmaceuticals International Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Valeant Pharmaceuticals International Inc. and related companies with MarketBeat.com's FREE daily email newsletter.